Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why

Shares of Marinus Pharmaceuticals Inc MRNS, a micro-cap biotech focused on therapies for neuropsychiatric disorders, are likely to see upside amid some key near-term events, according to Jefferies. 

The Analyst

Analyst Andrew Tsai initiated coverage of Marinus shares with a Buy rating and $10 price target.

The Thesis

Marinus' ganaxolone is being developed for neuropsychiatric disorders such as pediatric epilepsy, postpartum depression, or PPD, deadly seizures and potentially major depressive disorder, or MDD, Tsai said in a Tuesday note. 

MDD is a $5 billion-plus market opportunity, the analyst said. 

Tsai said he expects the stock to appreciate over the next six to 12 months due to the following four drivers:

  • A fuller Phase 2 PPD dataset for oral and intravenous-to-oral ganaxolone is due in the first half of 2019. The analyst said he believes Marinus needs to show similar efficacy as the preliminary data in more patients, as well as report no events of fainting — a key differentiating factor over rival SAGE Therapeutics Inc SAGE‘s brexanolone, which is two to three years ahead in development.
  • New Phase 2 data in deadly seizures is due in the first half of 2019. If it's positive, Tsai projects $2 to $4 per share in upside on a 35-50-percent probability of success.
  • The announcement of a new CEO.
  • Marinus is likely to release a strategy for MDD in the second half of 2019 or the first half of 2020.

Tsai also explored the possibility of Marinus unlocking the value of ganaxolone with a partnership or M&A.

"MRNS is an inexpensive name that offers a favorable setup at current price levels," the analyst said.

"The risk/reward for MRNS ($200-million cap) is skewed heavily toward the upside, as the Street appears to underappreciate [the company] having multiple shots on goal."

The Price Action

Marinus shares were up 9.55 percent at $3.90 at the time of publication Tuesday. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

OxyContin Maker Purdue Pharma's Legal Entanglement, Explained

Posted In: Andrew TsaiJefferiesAnalyst ColorBiotechPrice TargetInitiationAnalyst RatingsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.